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COVID-19, where Co stands for corona, VI stands for virus, and D denotes disease, in 
the recent past referred to as 2019 novel coronavirus or 2019-nCoV, has impacted 
numerous lives and businesses, and has led to a surreal emergency state within world 
communities. COVID-19 and the future emergence of dangerous viruses will have 
strong and as yet possibly unanticipated consequences and impact on the present and 
future use of cellular therapies. In this commentary, we offer a dispassionate 
assessment of where we believe COVID-19, as well as future emerging viruses, might 
compromise successful cell transplantation (Fig. 1). These therapies include 
hematopoietic cell transplantation (HCT) using umbilical cord blood (CB), bone marrow 
(BM), and mobilized peripheral blood, which contain hematopoietic stem (HSC) and 
progenitor (HPC) cells, as well as various cellular populations involved in the emerging 
fields of reparative and regenerative medicine. Such cell populations include HSC, 
HPC, mesenchymal stem/stromal cells (MSC), and immune cells such as lymphocytes 
used in chimeric antigen receptor (CAR) T-cell therapies, as well as pluripotent stem 
cell–based therapies. 
Concerns with COVID-19 and other-to-emerge viruses reflect the cells themselves, their 
collections, storage as cryopreserved cells, their in vitro modifications that include 
addition of new genes, and/or their expansion ex vivo, and the donors and recipients of 
these manipulated cells. With the outbreak of COVID-19 and the attendant concerns, 
fewer persons are currently donating cells for cellular therapies. The pool of available 
donors is already woefully inadequate. The current situation both literally and 
psychologically shrinks further the uninfected number of potential donors. This includes 
CB for HCT, those cells that have been donated since the known start of this highly 
infectious virus, and likely even CB stored prior to the start of the COVID-19 pandemic. 
All will have to be checked for the presence of COVID-19, and in the future for other 
emerging dangerous viruses. 
There is also the concern of how to ship these cellular sources for therapy (e.g., CB and 
BM) across countries. The National Marrow Donor Program has had to obtain special 
permission for transport of these precious lifesaving cells, and in these uncertain times, 
other shippers of cells for therapy may also need to obtain such special permission. So, 
why the concern for COVID-19 screening, even for many cells stored frozen (e.g., CB 
for CB banking efforts) in the recent and not so recent past? The cells stored frozen in a 
cryopreserved state may already have been infected with COVID-19. Cells frozen that 
are potentially contaminated with other infectious agents are usually not stored with 
those believed not to be contaminated. Moreover, viruses are very small particles, and if 
recent cell samples are placed in the same freezer tanks, the virus might be capable of 
breaching the freezer bag and surviving long enough to infect other stored frozen cells. 
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“Leakage” of the virus from one sample frozen bag to another in liquid nitrogen storage, 
especially in the gaseous phase of the liquid nitrogen, is not an impossible scenario. 
Caution indicates screening cells intended for cellular therapy before they are stored 
and again before they are used clinically. Stored cryopreserved CB units usually have 
small aliquots of the CB stored for analysis if needed, and these small samples can be 
tested for COVID-19. This would add to the extensive list of other infectious agents that 
are currently screened for by CB banking companies. This requires a rigorously reliable 
test to screen for COVID-19. 
Scientific and clinical investigators who are working with cells for cellular therapy, 
whether involved in research efforts or actual clinical transplantation, must assume that 
all the human samples they are working with may contain COVID-19, and continue to 
undertake the required rigorous safety precautions necessary to protect themselves. 
There is also the real concern that COVID-19 contamination might change the 
phenotypic and/or functional characteristics of the cells. This is presently an unknown, 
but the possibility exists that if the virus does influence the cells of interest, it could 
make it difficult to obtain consistent and reproducible results—a cornerstone for reliable 
scientific investigations. COVID-19 influences many organs, not just the lung, and what 
of cellular therapies using MSC and immune cells, such as CART cells? CART cell 
therapy is associated with the devastating side effects elicited by the CART cell-induced 
cytokine storm. While investigators have been dealing with efforts to dampen the life-
threatening side effects of the CART cell-induced cytokine storm, how will COVID-19, if 
present in the CART cells, donors, or recipients of these cells, impact this promising 
treatment? Viruses are known to induce cytokine release. Will COVID-19 exacerbate 
the cytokine storm elicited by the CART cells? 
This then brings us to the recipients of HCT and other cellular therapies. In the short 
term, transplants as well as other procedures are necessarily being scaled back 
because of the risk of exposure to a potentially immunocompromised recipient, the lack 
of available ventilators for the recipient, and the current inability to assess whether the 
transplant is infected. If the recipients are infected with COVID-19, even if it only elicits 
mild effects that allow for recovery, how will the virus in the recipients influence the 
infused cells? In HCT, especially with CB, would this result in delayed time to 
engraftment for each donor cell type, lower survival, increased relapse rates, and acute 
and chronic graft-versus-host disease? Pregnant recipients have the further potential 
concern, as recent news reports suggest, that COVID-19 can even cross the mother–
child placental barrier. 
We are currently in the midst of uncertain times regarding the potential impact and 
influences of COVID-19 and a future of continuing emergence of dangerous viruses on 
cell products and their use in cellular therapies. It is important that we seriously consider 
how these viruses will now and in the future affect the cell products, the storage of 
cryopreserved cells, and their use for various renditions of cellular therapy, including 
that of reparative and regenerative medicine. Internationally, health organizations and 
scientific societies are offering guidance on COVID-19 and stem-cell transplants and 
surveying their members on future patient impact (see Table 1 for some examples). 
Now, not later, is the time to begin scientific investigations into the potential roles of 
COVID-19 and other-to-emerge viruses, not just for the potential to infect recipients of 
the cellular therapies, but also for how they might influence the cell products and their 
use for recipients in need of these valuable and in some cases lifesaving therapies. 
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FIG. 1. Potential stages of impact for emerging viruses on cellular therapies: anticipating risk points for 
viral infection during cellular therapy. 
 
 
 
 
 
 
 
 
 
Table 1. Health Organization and Scientific Society Guidance on Impact of COVID-19 on Stem-Cell Transplants 
American Society for 
Transplantation and Cellular 
Therapy 
https://www.astct.org/communities/community-
home?CommunityKey=d3949d84-3440-45f4-8142-90ea05adb0e5 
American Society of Hematology https://www.hematology.org/COVID-19 
American Society of 
Transplantation https://www.myast.org/covid-19-information 
European Society for Blood and 
Marrow Transplantation https://www.ebmt.org/covid-19-and-bmt 
The Lancet https://www.thelancet.com/coronavirus 
The Transplantation Society https://www.tts.org/covid-19 
World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
 
